Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MasterAlgaeon Oct 24, 2020 11:03am
290 Views
Post# 31776474

Glaxo Big name partner rumor

Glaxo Big name partner rumorGlaxoSmithKline has one drug in Phase 1 for osteoarthritis pain. Very early stages - no name yet just a number. See their 2019 annual report.

Tanezumab (anti-nerve growth factor drug) - is collaberation between Pfizer Eli Lilly & Co. and is being tested for osteoarthritis pain, and for other pain like lower back and cancer pain.
According to an Oct 14th article by Motly Fool "The company currently awaits regulatory approvals for four programs, including new pain drug tanezumab."

According to an Oct 16th article by Zacks "A notable pipeline candidate in Lily’s [sic] portfolio for the pain indication is tanezumab. It is being developed in a late-stage study for osteoarthritis pain and is currently under review in the United States and Europe for the given indication. It is also being evaluated in a phase III study for treating cancer pain."

Doubtful that Pfizer and Lilly would cannabilize years of research to get Oten...

So Glaxo?

Bullboard Posts